On this page
What happened
On August 27, 2026, FDA reported adverse events in at least 30 patients after intravenous glutathione, alone or with other ingredients. Different compounding pharmacies had sourced dietary-supplement-grade glutathione from Medisca lot 229536. Two Texas pharmacies recalled injectable products after finding elevated endotoxin. Reported symptoms included fever, chills, dizziness and sepsis-like reactions, with some hospitalizations. The agency described an ongoing investigation, rather than a completed estimate of every exposed patient’s risk.
Why it matters
The central issue is manufacturing quality for the intended route of administration. A material supplied for dietary use is not automatically appropriate for injection; contaminants tolerated or handled differently through one route can pose different problems through another. FDA said Medisca warned U.S. customers on August 20 against using this grade for injectables. It also stressed that testing alone cannot replace quality controls across ingredient sourcing and compounding.
Scope and limitations
FDA urged affected compounders to contact customers and discontinue the implicated IV products. The alert cited earlier communication in 2019, showing this was a recurring quality concern. It did not investigate cognitive enhancement, establish the same risk for all oral glutathione products, or report that every possible endotoxin symptom occurred in this cluster. Readers should keep the lot, route and formulation distinctions intact rather than translate an injectable-product alert into a claim about every supplement bearing the ingredient name.
This sourced news summary and translation were prepared with AI assistance. Source links, the news date and research limitations are disclosed; this is not a claim of independent medical expert review. News production method.
Sources
- FDA reminds compounders not to use dietary supplement grade glutathione for injectables — U.S. Food and Drug Administration ·
Research news is not medical advice or a recommendation to use a substance. Read findings in the context of the study design, participants and limitations. Editorial standards.
← All news